Edgewise Therapeutics: How a $1.35 Billion Gain Transformed Its Q3

As seen on the 24/7 Wall St. homepage on November 4, 2026.

EWTX Edgewise Therapeutics
Q3 2026
EPS
$9.65
est $2.51 +284.0%
Revenue
$0K

The sale of the sevasemten muscular dystrophy program to Servier booked a $1.35 billion gain, flipping a chronically loss-making biotech to GAAP profit. Operations still burned, and all of that cash now rides on cardiovascular: a Phase 3 HCM trial of EDG-7500 is due to start by year-end.

Continue ReadingShow less

Edgewise Therapeutics reported Q3 2026 GAAP earnings per share of $9.65, far exceeding expectations against a consensus estimate of $2.51. Edgewise has generated zero revenue, as expected, and its core operations burned through $46.14 million in the quarter. The headline number was almost entirely the product of a single, transformative transaction.

In July 2026, Edgewise closed the sale of its sevasemten muscular dystrophy program to French pharmaceutical company Servier, receiving $1.40 billion in upfront cash proceeds. That deal produced a recognized gain of $1.35 billion, which, after $155.3 million in associated income tax expense, swung the company from a net loss of $40.67 million in the prior-year quarter to net income of $1.17 billion. Without that transaction, the operating picture would have looked very similar to recent quarters.

The sale also reshaped Edgewise's balance sheet substantially. The company ended September with $1.74 billion in cash and marketable securities, giving it a long runway to pursue a now-concentrated cardiovascular strategy. Total assets reached $1.78 billion, up more than 205% year over year, while shareholders' equity stood at $1.63 billion.

Sponsored

The entire future of the company now hinges on EDG-7500, an oral cardiac sarcomere modulator targeting hypertrophic cardiomyopathy, or HCM. CEO Kevin Koch noted that positive results from the Phase 2 CIRRUS-HCM Part D trial were presented as late-breaking science at ESC Congress in August 2026, and that a Phase 3 trial covering both obstructive and nonobstructive HCM is on track to begin by year-end 2026. A publication in JCI Insight has also detailed EDG-7500's preclinical pharmacologic profile.

Edgewise is also moving into heart failure with a second asset. The Phase 2 EQUINOX-HFpEF trial of EDG-15400, a selective cardiac sarcomere modulator aimed at impaired cardiac relaxation, has dosed its first patient. The company has flagged its substantial dependence on EDG-7500's success as a key risk, along with a possible need for additional capital and the usual uncertainties around clinical trial outcomes and regulatory approvals.

Mentioned: EWTX